A deficiency of L-arginine, an increase in endogenous NOS inhibitors, a decrease in the activity of NOS, and increased levels of asymmetric dimethyl arginine (ADMA), a potent endogenous competitive inhibitor of NOS, in CKD were documented over time in some studies [57,58]. This evidence concerns the gene NOS2 and chronic kidney disease.